α‐Cembrenediol exhibits a wide range of biological activities, including antibacterial, antitumor, and neuroprotective effects. However, knowledge of the absorption, transport, and release of α‐cembrenediol in drug metabolism within the body is currently limited. Therefore, we aimed to gain a comprehensive understanding of the in vivo transport, distribution, and elimination mechanisms of α‐cembrenediol and investigate the interaction between α‐cembrenediol and HSA. To this end, we utilized various methods including UV absorption spectroscopy, steady‐state fluorescence analysis, circular dichroism measurements, molecular docking studies, and molecular dynamics simulations. The results of the UV and fluorescence spectra clearly demonstrated that HSA interacts with α‐cembrenediol. Specifically, the fluorescence spectra results showed that at a temperature of 310 K, the fluorescence quenching constant (KSV) and binding constant (Kb) between HSA and α‐cembrenediol were determined to be 1.28 × 103 Lmol−1 and 218.27 Lmol−1, respectively. As the temperature was decreased from 310 K to 293 K, both KSV and Kb values increased, indicating the presence of a static quenching mechanism throughout the interaction process. Moreover, the results indicated the presence of a singular, specific binding site for α‐cembrenediol on HSA, as evidenced by an approximate count of one binding site at all three temperatures. Additionally, this binding process occurred spontaneously (ΔG < 0), with van der Waals interactions and hydrogen bonding as the primary driving forces (ΔH = −9.40 kJmol−1 and ΔS = −14.50 Jmol−1·K−1). The binding of α‐cembrenediol to Sudlow site I of HSA was confirmed through molecular docking, a combination of fluorescence probe substitution, and molecular dynamics simulation experiments. Moreover, the results demonstrated that α‐cembrenediol binding led to alterations in the structural conformation of HSA, as confirmed by three‐dimensional fluorescence, synchronous fluorescence, and circular dichroism spectra. This study offers crucial insights into the interaction between α‐cembrenediol and HSA, contributing to an improved understanding of the compound’s pharmacokinetic properties.